| Savanna Duggan, OTR | |
|
851 Penniman Ave, Plymouth, MI 48170-1621 | |
| (248) 349-9595 | |
| (989) 509-5965 |
| Full Name | Savanna Duggan |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 851 Penniman Ave, Plymouth, Michigan |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033980321 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | 5201010928 (Michigan) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Savanna Duggan, OTR 851 Penniman Ave, Plymouth, MI 48170-1621 Ph: (248) 349-9595 | Savanna Duggan, OTR 851 Penniman Ave, Plymouth, MI 48170-1621 Ph: (248) 349-9595 |
News Archive
CytomX, a biotechnology company developing Probody™ therapeutics for the treatment of cancer, today announced the closing of a $70 million Series D financing round. The financing was led by Fidelity Management & Research Company with participation from Casdin Capital, Cormorant Asset Management, Deerfield Management, Perceptive Advisors, Redmile Group, Tekla Healthcare Investors and Tekla Life Sciences Investors, Venrock Healthcare Capital Partners, Wellington Management Company and additional undisclosed investors.
Frozen and freeze-dried products for Fecal Microbiota Transplantation are nearly as effective as fresh product at treating patients with Clostridium difficile infection, according to researchers at The University of Texas Health Science Center at Houston School of Public Health and Kelsey Research Foundation.
Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBIN™ (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).
In-school COVID-19 transmission is rare - even among close school contacts of those who test positive for the virus - when schools heed public health precautions such as mandatory masking, social distancing and frequent hand-washing, according to results of a pilot study in Missouri aimed at identifying ways to keep elementary and secondary schools open and safe during the pandemic.
› Verified 8 days ago
Ulysses Monroe, Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 801 W Ann Arbor Trl, Suite 220, Plymouth, MI 48170 Phone: 866-991-0900 | |
Jessica A Kenyon, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 15870 N Haggerty Rd, Plymouth, MI 48170 Phone: 734-420-7917 | |
Nikkia Wheeler, OTRL Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 46200 Port St, Plymouth, MI 48170 Phone: 734-454-0866 | |
Sylvia Sartorelli, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 729 W Ann Arbor Trl, Plymouth, MI 48170 Phone: 734-398-3444 | |
Whooby Deriveau, Occupational Therapist Medicare: Medicare Enrolled Practice Location: 44670 Ann Arbor Rd W Ste 130, Plymouth, MI 48170 Phone: 313-278-4601 | |
Dan Diamond, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 127 S Main St, Suite 111, Plymouth, MI 48170 Phone: 734-354-8000 Fax: 734-207-5291 | |
Alexa Edwards, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 801 W Ann Arbor Trl Ste 220, Plymouth, MI 48170 Phone: 866-991-0900 |